[{"orgOrder":0,"company":"HavaH Therapeutics","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","amount":"$11.2 million","upfrontCash":"$0.5 million","newsHeadline":"Clarus Therapeutics and HavaH Therapeutics Announce Licensing Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"N\/A","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Immunology","graph2":"N\/A"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Juvise Pharmaceuticals Successfully Syndicated Its EUR 213 Million Financing in Less than One Month","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali\u00ae Prolonged PFS Benefit for Pre- and Perimenopausal Patients with Aggressive HR+\/HER2\u2212 Metastatic Breast Cancer Compared to Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali\u00ae Phase III NATALEE Trial Meets Primary Endpoint at Interim Analysis Demonstrating Clinically Meaningful Benefit in Broad Population of Patients with Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio\u00ae (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Anastrozole
MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Verzenio (abemaciclib) is a small molecule CDK4/CD6 inhibitor which is under phase 3 clinical development in combination with anastrozole for the treatment of post-menopausal patients with HR+/HER2-, advanced or metastatic breast cancer.
Kisqali® (ribociclib) is the only USFDA approved category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI.
ONA-XR (onapristone) is a selective progesterone receptor (PR) antagonist designed to block both ligand dependent and ligand-independent activity of PR which downregulates cancer stem cellmobilization, and blocking immune evasion.
Kisqali (ribociclib) is the only CDK4/6 inhibitor with proven overall survival benefit across all three pivotal Phase III advanced breast cancer trials and is recognized as the only CDK4/6i with overall survival benefit in first-line HR+/HER2- advanced breast cancer.
CLAR-121 is combination of testosterone undecanoate (natural ligand for the androgen receptor and anastrozole delivered by a subcutaneous implant for treatment of AR-mediated inflammatory breast disease that predominantly affects women.
CLAR-121 is a proprietary combination of testosterone (T) (natural ligand for the androgen receptor; AR) and anastrozole (inhibitor of T conversion to estradiol) delivered by a subcutaneous implant for treatment of AR-mediated breast disease that predominantly affects women.
Arimidex® (anastrozole) and Casodex® (bicalutamide) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians.